KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI

On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading

KEI and T1International comments on the prospective grant of an exclusive license to Inversago Pharma, Inc

On August 20, 2018, KEI and T1International filed comments to the NIH regarding the prospective grant of an exclusive license to Inversago Pharma, a firm headquartered in Canada. According to the Federal Register notice 83 FR 38707, the NIH exclusive… Continue Reading

KEI and UACT comments on the prospective grant of an exclusive license to Midissia Therapeutics

Below are the comments filed by Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) regarding a prospective grant of an exclusive license of NIH-owned patents to the California-based company Midissia Therapeutics. The prospective exclusive license is… Continue Reading

2018: NIH licenses on Anti-Mesothelin CAR to Atara Biotherapeutics

Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading

KEI comments on the prospective grant of an exclusive patent license: Mutant IDH1 inhibitors useful for treating cancer to Apexx Oncology

July 10, 2018 Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager National Center for Advancing Translational Sciences National Institutes of Health Email sury.vepa@nih.gov Re: Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer to Apexx… Continue Reading

NIH asked to extend comments on proposed license to Atara Biotherapeutics for patents on Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Human Cancer

On July 9, 2018, KEI asked the NIH to extend the deadline for comments described on the Federal Register notice 83 FR 30448 until information about the enrollment and costs of NIH-funded clinical trials involving mesothelin expressing cancers, and trials… Continue Reading

Litigation: KEI v. NIH et al.

On April 19, 2018, KEI filed a lawsuit against the NIH license of CD30 CAR T patents to Gilead. This page provides current information on this ongoing litigation. KEI blogs 2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR… Continue Reading

KEI comments on prospective exclusive NIH license to streptococcus pneumonia patents, for the University of Liverpool

On July 2, 2018, Knowledge Ecology International (KEI) filed comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to the University of Liverpool, located in the U.K. The inventions described in the Federal… Continue Reading

NIH Declines Request for the Budget for Clinical Trials Involving CAR T technology to be licensed to Kite/Gilead

On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading